From fibrinolysis to the plasminogen-plasmin system and beyond: A remarkable growth of knowledge, with personal observations on the history of fibrinolysis

Seminars in Thrombosis and Hemostasis

Volumn 40, Issue 5, 2014, Pages 585-591

  Kwaan, Hau C ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

fibrinolysis; PAI 1; plasminogen; plasminogen activator

Indexed keywords

FIBRINOLYTIC AGENT; PLASMIN; PLASMINOGEN; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERPINE1 PROTEIN, HUMAN;

ARTICLE; AUTOPSY; BLOOD CLOT LYSIS; CELL MIGRATION; EMBRYO DEVELOPMENT; FIBRINOLYSIS; PRIORITY JOURNAL; WOUND HEALING; ANIMAL; BLOOD; FIBRINOLYTIC THERAPY; HISTORY; HUMAN; NEOPLASM; PHYSIOLOGY;

ANIMALS; FIBRINOLYSIN; FIBRINOLYSIS; HISTORY, 18TH CENTURY; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; NEOPLASMS; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOLYTIC THERAPY;

EID: 84905251142     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0034-1383545     Document Type: Article

References (142)

1. Morgagni G. B. Founders of Modern Medicine: Giovanni Battista Morgagni. (1682-1771). Med Library Hist J: 1903; 1 270 277
2. Hunter J. A treatise on the blood, inflammation, and gun-shot wounds, by the late John Hunter. To which is prefixed, A short account of the author's life, by his brother-in-law, Everard Home. London printed by John Richardson, for George Nicol: 1794
3. Virchow R. Die cellularpathologie: 1871; 194
4. Morawitz P. Uber einige post-mortale blutveranderunguen. Beitr z chem Physiol u Path: 1906; 8 1 10
5. Yudin S. S. Transfusion of cadaver blood. J Am Med Assoc: 1936; 106 997 999
6. Denis P. Essai sur l'application de la chimie a l'etude physiologique du sang de l'homme, et a l'etude physiologico-pathologique, hygienique et therapeutiques de maladies de cette humeur. Paris Bechet jne: 1838
7. Green J. R. Note on the Action of Sodium Chloride in dissolving Fibrin. J Physiol: 1887; 8 6 372 377
8. Dastre A. Fibrinolyse dans le sang. Arch de physiol norm et path: 1893; 5 661 663
9. Hedin S. G. On the presence of a proteolytic enzyme in the normal serum of the ox. J Physiol: 1903; 30 2 195 201
10. Opie E. L., Barker B. I. Leucoprotease and anti-leucoprotease of mammals and of birds. J Exp Med: 1907; 9 2 207 221
11. Sur R. F. les proteinases contenues dans la fraction acidglobulines de divers plasma. Schweiz Med Wochenschr: 1942; 72 156 172
12. Tillett W. S., Garner R. L. The Fibrinolytic Activity of Hemolytic Streptococci. J Exp Med: 1933; 58 4 485 502
13. Milstone J. H. A factor in normal human blood which participates in streptococcal fibrinolysis. J Immunol: 1941; 42 109 116
14. Kaplan M. H. Nature and role of the lytic factor in hemolytic streptococcal fibrinolysis. Proceedings of the Society of Experimental Biology, New York: 1944; 57 40 50
15. Christensen L. R. Streptococcal Fibrinolysis: A Proteolytic Reaction Due to a Serum Enzyme Activated by Streptococcal Fibrinolysin. J Gen Physiol: 1945; 28 4 363 383
16. Christensen L. R., Macleod C. M. A Proteolytic Enzyme of Serum: Characterization, Activation, and Reaction with Inhibitors. J Gen Physiol: 1945; 28 6 559 583
17. Tillett W. S., Sherry S. The effect in patients of streptococcal fibrinolysin and streptococcal desoxyribonuclease on fibrinous, purulent, and sanguinous pleural exudations. J Clin Invest: 1949; 28 173 190
18. Fletcher A. P., Alkjaersig N., Smyrniotis F. E., Sherry S. The treatment of patients suffering from early myocardial infarction with massive and prolonged streptokinase therapy. Trans Assoc Am Physicians: 1958; 71 287 296
19. Imperati L. Contributo sperimentale alla interprezione del mechanismo causale fibrinolisi post-opertoria. Rivdi patsper: 1939; 23 313 316
20. Rocha e silva M., Andrade S. O., Teixeira R. M. Fibrinolysis in peptone and anaphylactic shock in the dog. Nature: 1946; 157 801
21. Tagnon H. J., Levenson S. M. et al. The occurrence of fibrinolysis in shock, with observations on the prothrombin time and the plasma fibrinogen during hemorrhagic shock. Am J Med Sci: 1946; 211 88 96
22. Fantl P., Simon S. E. Fibrinolysis following electrically induced convulsions. Aust J Exp Biol Med Sci: 1948; 26 Pt. 6 521 529
23. Macfarlane R. G. Fibrinolysis following operation. Lancet: 1937; i 10 12
24. Truelove S. C. Fibrinolysis and eosinopenia after surgical operations. Clin Sci (Lond): 1952; 11 2 107 112
25. Biggs R., MacFARLANE R. G., Pilling J. Observations on fibrinolysis; experimental activity produced by exercise or adrenaline. Lancet: 1947; 1 6448 402 405
26. Stefanini M. Fibrinolysis and fibrinolytic purpura Blood: 1952; 7 10 1044 1046
27. Crosby W. H., Stefanini M. Pathogenesis of the plasma transfusion reaction with especial reference to the blood coagulation system. J Lab Clin Med: 1952; 40 3 373 386
28. Ungar G., Damgaard E. Protein breakdown in thermal injury. Proc Soc Exp Biol Med: 1954; 87 2 378 383
29. Tagnon H. J., Schulman P., Whitmore W. F., Leone L. A. Prostatic fibrinolysin; study of a case illustrating role in hemorrhagic diathesis of cancer of the prostate. Am J Med: 1953; 15 6 875 884
30. Moloney W. C., Egan W. J., Gorman A. J. Acquired afibrinogenemia in pregnancy. N Engl J Med: 1949; 240 15 596 598
31. Weiner A. E., Reid D. E., Roby C. C. Coagulation defects associated with premature separation of the normally implanted placenta. Am J Obstet Gynecol: 1950; 60 2 379 386
32. Dieckmann W. J. Blood chemistry and renal function in abruptio placentae. Am J Obstet Gynecol: 1936; 31 734 745
33. Coon W. W., Hodgson P. E. Fibrinolysis in surgery patients. I. Possible relationship to a hemorrhagic diathesis. Surg Gynecol Obstet: 1952; 95 6 717 724
34. Cliffton E. E., Grossi C., Siegel M. Hemorrhage during and after operation secondary to changes in the clotting mechanism; physiology and methods of control. Surgery: 1956; 40 37 51; discussion, 51-53
35. Ratnoff O. D. Studies on a proteolytic enzyme in human plasma. VII. A fatal hemorrhagic state associated with excessive plasma proteolytic activity in a patient undergoing surgery for carcinoma of the head of the pancreas. J Clin Invest: 1952; 31 5 521 528
36. Goodpasturl E. W. Fibrinolysis in chronic hepatic insufficiency. Bull Johns Hopkins Hosp: 1914; 25 330 336
37. Ratnoff O. D. Studies on a proteolytic enzyme in human plasma; the rate of lysis of plasma clots in normal and diseased individuals, with particular reference to hepatic diseases. Bull Johns Hopkins Hosp: 1949; 84 1 29 42
38. Kwaan H. C., McFadzean A. J. Plasma fibrinolytic activity in cirrhosis of the liver. Lancet: 1956; 270 6929 968 969
39. Kwaan H. C., McFadzean A. J., Cook J. On plasma fibrinolytic activity in cryptogenetic splenomegaly. Scott Med J: 1957; 2 4 137 150
40. Kwaan H. C., Lo R., McFadzean A. J. The production of plasma fibrinolytic activity in vivo by serotonin (5-hydroxytryptamine) creatinine sulphate. Clin Sci (Lond): 1957; 16 2 255 259
41. Kwaan H. C., Lo R., McFadzean A. J. On the production of plasma fibrinolytic activity within veins. Clin Sci (Lond): 1957; 16 2 241 253
42. Kwaan H. C., Lo R., Mcfadzean J. S. On the lysis of thrombi experimentally produced within veins. Br J Haematol: 1958; 4 1 51 62
43. O'Rourke J., Jiang X., Hao Z., Cone R. E., Hand A. R. Distribution of sympathetic tissue plasminogen activator (tPA) to a distant microvasculature. J Neurosci Res: 2005; 79 6 727 733 (Pubitemid 40476497)
44. Hao Z., Guo C., Jiang X., et al. New transgenic evidence for a system of sympathetic axons able to express tissue plasminogen activator (t-PA) within arterial/arteriolar walls. Blood: 2006; 108 1 200 202 (Pubitemid 43990629)
45. Kwaan H. C., McFadzean A. J. The inhibition of clot lysis by corticotrophin. Lancet: 1956; 270 6908 136 137
46. Astrup T. The biological significance of fibrinolysis. Lancet: 1956; 271 6942 565 568
47. Astrup T. Fibrinolysis in the organism. Blood: 1956; 11 9 781 806
48. Astrup T., Sterndorff I. Fibrinolysokinase activity in animal and human tissue. Acta Physiol Scand: 1956; 37 1 40 47
49. Astrup T. Fibrinolysis. Acta Haematol: 1952; 7(5) 271 280
50. Astrup T., Sterndorff I. Fibrinolytic activity of tissue extracts and of trypsin. Nature: 1952; 170 4336 981
51. Astrup T., Stage A. Isolation of a soluble fibrinolytic activator from animal tissue. Nature: 1952; 170 4335 929
52. Astrup T., Albrechtsen O. K. Estimation of the plasminogen activator and the trypsin inhibitor in animal and human tissues. Scand J Clin Lab Invest: 1957; 9 3 233 243
53. Albrechtsen O. K. The fibrinolytic activity of human tissues. Br J Haematol: 1957; 3 3 284 291
54. Albrechtsen O. K. The fibrinolytic activity of animal tissues. Acta Physiol Scand: 1957; 39 2-3 284 290
55. Todd A. S. The histological localisation of fibrinolysin activator. J Pathol Bacteriol: 1959; 78 281 283
56. Kwaan H. C., Astrup T. Localization of Fibrinolytic Activity in the Eye. Arch Pathol: 1963; 76 595 601
57. Kwaan H. C., Astrup T. Demonstration of cellular fibrinolytic activity by the histochemical fibrin slide technique. Lab Invest: 1967; 17 2 140 145
58. Kwaan H. C., Cocco A., Mendeloff A. I., Astrup T. Fibrinolytic activity in the normal and inflamed rectal mucosa. Scand J Gastroenterol: 1969; 4 5 441 445
59. Kwaan H. C., Astrup T. Fibrinolytic Activity of Reparative Connective Tissue. J Pathol Bacteriol: 1964; 87 409 414
60. Kwaan H. C., Astrup T. Localization of Fibrinolytic Activity in Myocardial Infarcts in Rats. Thromb Diath Haemorrh: 1964; 12 407 417
61. Kwaan H. C., Astrup T. Fibrinolytic activity in thrombosed veins. Circ Res: 1965; 17 6 477 483
62. Kwaan H. C., Astrup T. Fibrinolytic activity in human atherosclerotic coronary arteries. Circ Res: 1967; 21 6 799 804
63. Kwaan H. C., Albrechtsen O. K. Histochemical study of fibrinolytic activity in the rat uterus in normal and hormonally induced estrus. Am J Obstet Gynecol: 1966; 95 4 468 473
64. Kwaan H., Markus G. Cell biology of fibrinolysis. Tenth International Congress on Fibrinolysis. August 1990. Semin Thromb Hemost: 1991; 17 3 159 312
65. Kwaan H. C. The biologic role of components of the plasminogen-plasmin system. Prog Cardiovasc Dis: 1992; 34 5 309 316
66. Castellino F. J., Violand B. N. The fibrinolytic system-basic considerations. Prog Cardiovasc Dis: 1979; 21 4 241 254
67. Ploug M., Ronne E., Behrendt N., Jensen A. L., Blasi F., Dano K. Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem: 1991; 266 3 1926 1933 (Pubitemid 21908387)
68. Cesarman G. M., Guevara C. A., Hajjar K. A. An endothelial cell receptor for plasminogen/tissue plasminogen activator (t-PA). II. Annexin II-mediated enhancement of t-PA-dependent plasminogen activation. J Biol Chem: 1994; 269 33 21198 21203
69. Hajjar K. A., Jacovina A. T., Chacko J. An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. Identity with annexin II. J Biol Chem: 1994; 269 33 21191 21197
70. Hajjar K. A., Menell J. S. Annexin II: a novel mediator of cell surface plasmin generation. Ann N Y Acad Sci: 1997; 811 337 349 (Pubitemid 27308339)
71. Miles L. A., Parmer R. J. Plasminogen receptors: the first quarter century. Semin Thromb Hemost: 2013; 39 4 329 337
72. O'Connell P. A., Madureira P. A., Berman J. N., Liwski R. S., Waisman D. M. Regulation of S100A10 by the PML-RAR-α oncoprotein. Blood: 2011; 117 15 4095 4105
73. Loskutoff D. J., van Mourik J. A., Erickson L. A., Lawrence D. Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells. Proc Natl Acad Sci USA: 1983; 80 10 2956 2960 (Pubitemid 13104156)
74. Nielsen L. S., Lecander I., Andreasen P. A., Henschen A., Astedt B., Dano K. Plasminogen activator inhibitors from placenta and fibrosarcoma cells are antigenically different as evaluated with monoclonal and polyclonal antibodies. Thromb Res: 1987; 46 3 411 423 (Pubitemid 17076045)
75. Lecander I., Astedt B. Specific plasminogen activator inhibitor of placental type PAI 2 occurring in amniotic fluid and cord blood. J Lab Clin Med: 1987; 110 5 602 605 (Pubitemid 18033251)
76. Heeb M. J., España F., Geiger M., Collen D., Stump D. C., Griffin J. H. Immunological identity of heparin-dependent plasma and urinary protein C inhibitor and plasminogen activator inhibitor-3. J Biol Chem: 1987; 262 33 15813 15816 (Pubitemid 17165185)
77. Strickland S., Reich E., Sherman M. I. Plasminogen activator in early embryogenesis: enzyme production by trophoblast and parietal endoderm. Cell: 1976; 9 2 231 240
78. Strickland S., Beers W. H. Studies on the role of plasminogen activator in ovulation. In vitro response of granulosa cells to gonadotropins, cyclic nucleotides, and prostaglandins. J Biol Chem: 1976; 251 18 5694 5702
79. Beers W. H., Strickland S., Reich E. Ovarian plasminogen activator: relationship to ovulation and hormonal regulation. Cell: 1975; 6 3 387 394
80. Friedman G. C., Seeds N. W. Tissue plasminogen activator expression in the embryonic nervous system. Brain Res Dev Brain Res: 1994; 81 1 41 49 (Pubitemid 24246409)
81. Reddington M., Haas C., Kreutzberg G. W. The plasminogen activator system in neurons and glia during motoneuron regeneration. Neuropathol Appl Neurobiol: 1994; 20 2 188 190 (Pubitemid 24123557)
82. Melchor J. P., Strickland S. Tissue plasminogen activator in central nervous system physiology and pathology. Thromb Haemost: 2005; 93 4 655 660 (Pubitemid 40485400)
83. Strickland S. Tissue plasminogen activator in nervous system function and dysfunction. Thromb Haemost: 2001; 86 1 138 143 (Pubitemid 32663946)
84. Schaefer U., Machida T., Vorlova S., Strickland S., Levi R. The plasminogen activator system modulates sympathetic nerve function. J Exp Med: 2006; 203 9 2191 2200 (Pubitemid 44352239)
85. Jiang Q., Yasothornsrikul S., Taupenot L., Miles L. A., Parmer R. J. The local chromaffin cell plasminogen/plasmin system and the regulation of catecholamine secretion. Ann N Y Acad Sci: 2002; 971 445 449 (Pubitemid 35305336)
86. Syrovets T., Lunov O., Simmet T. Plasmin as a proinflammatory cell activator. J Leukoc Biol: 2012; 92 3 509 519
87. Romer J., Bugge T. H., Pyke C. et al. Plasminogen and wound healing. Nat Med: 1996; 2 7 725
88. Creemers E., Cleutjens J., Smits J. et al. Disruption of the plasminogen gene in mice abolishes wound healing after myocardial infarction. Am J Pathol: 2000; 156 6 1865 1873 (Pubitemid 30641756)
89. Suelves M., Vidal B., Ruiz V. et al. The plasminogen activation system in skeletal muscle regeneration: antagonistic roles of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1). Front Biosci: 2005; 10 2978 2985 (Pubitemid 40910536)
90. Kwaan H. C., Keer H. N. Fibrinolysis and cancer. Semin Thromb Hemost: 1990; 16 3 230 235 (Pubitemid 20289930)
91. Kwaan H. C. The plasminogen-plasmin system in malignancy. Cancer Metastasis Rev: 1992; 11 3-4 291 311
92. Dano K., Behrendt N., Hoyer-Hansen G. et al. Plasminogen activation and cancer. Thromb Haemost: 2005; 93 4 676 681 (Pubitemid 40485402)
93. Nicholl S. M., Roztocil E., Davies M. G. Plasminogen activator system and vascular disease. Curr Vasc Pharmacol: 2006; 4 2 101 116 (Pubitemid 46785385)
94. Collen D., Lijnen H. R. Thrombolytic agents. Thromb Haemost: 2005; 93 4 627 630 (Pubitemid 40485396)
95. Sherry S. The fibrinolytic activity of streptokinase activated human plasmin. J Clin Invest: 1954; 33 7 1054 1063
96. Collen D. The plasminogen (fibrinolytic) system. Thromb Haemost: 1999; 82 2 259 270
97. Kwaan H. C., Markus G. Cell biology of fibrinolysis. Semin Thromb Hemost: 1991; 17 161 312
98. Kwaan H. C., Mazar A. P. Biologic role of the plasminogen-plasmin system: thrombolysis, bleeding, and beyond. Semin Thromb Hemost: 2013; 39 4 327 328
99. Carrel A., Burrows M. T. Cultivation in Vitro of Malignant Tumors. J Exp Med: 1911; 13 5 571 575
100. Ossowski L., Quigley J. P., Kellerman G. M., Reich E. Fibrinolysis associated with oncogenic transformation. Requirement of plasminogen for correlated changes in cellular morphology, colony formation in agar, and cell migration. J Exp Med: 1973; 138 5 1056 1064
101. Astedt B., Holmberg L. Immunological identity of urokinase and ovarian carcinoma plasminogen activator released in tissue culture. Nature: 1976; 261 5561 595 597
102. Kwaan H. C., McMahon B. The role of plasminogen-plasmin system in cancer. Cancer Treat Res: 2009; 148 43 66
103. Kwaan H. C., Mazar A. P., McMahon B. J. The apparent uPA/PAI-1 paradox in cancer: more than meets the eye. Semin Thromb Hemost: 2013; 39 4 382 391
104. Duffy M. J. The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des: 2004; 10 1 39 49 (Pubitemid 38072742)
105. Duffy M. J. Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies. Clin Chem: 2002; 48 8 1194 1197 (Pubitemid 34809824)
106. Look M., van Putten W., Duffy M. et al. Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients. Thromb Haemost: 2003; 90 3 538 548 (Pubitemid 37142426)
107. Jänicke F., Prechtl A., Thomssen C., et al. German N0 Study Group. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 J Natl Cancer Inst: 2001; 93 12 913 920
108. Harbeck N., Schmitt M., Paepke S., Allgayer H., Kates R. E. Tumor-associated proteolytic factors uPA and PAI-1: critical appraisal of their clinical relevance in breast cancer and their integration into decision-support algorithms. Crit Rev Clin Lab Sci: 2007; 44 2 179 201
109. Harris L., Fritsche H., Mennel R., et al. American Society of Clinical Oncology. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol: 2007; 25 33 5287 5312 (Pubitemid 350232263)
110. Annecke K., Schmitt M., Euler U. et al. uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial. Adv Clin Chem: 2008; 45 31 45
111. Duffy M. J., Duggan C. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer. Clin Biochem: 2004; 37 7 541 548 (Pubitemid 38845017)
112. Duffy M. J., Sturgeon C., Lamerz R. et al. Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol: 2010; 21 3 441 447
113. Schmitt M., Harbeck N., Brünner N. et al. Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev Mol Diagn: 2011; 11 6 617 634
114. Cantero D., Friess H., Deflorin J. et al. Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br J Cancer: 1997; 75 3 388 395 (Pubitemid 27051054)
115. Gutova M., Najbauer J., Gevorgyan A. et al. Identification of uPAR-positive chemoresistant cells in small cell lung cancer. PLoS ONE: 2007; 2 2 e243
116. Soff G. A., Sanderowitz J., Gately S. et al. Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. J Clin Invest: 1995; 96 6 2593 2600
117. Rabbani S. A., Ateeq B., Arakelian A. et al. An anti-urokinase plasminogen activator receptor antibody (ATN-658) blocks prostate cancer invasion, migration, growth, and experimental skeletal metastasis in vitro and in vivo. Neoplasia: 2010; 12 10 778 788
118. Meyer J. E., Brocks C., Graefe H. et al. The Oral Serine Protease Inhibitor WX-671 - First Experience in Patients with Advanced Head and Neck Carcinoma. Breast Care (Basel): 2008; 3 s 20 24
119. Heinemann V. EM, Pinter T., Mala C., Nevile N., Bevan P. Randomized Phase II trial with an uPA inhibitor (WX-671) in patients with locally advanced non-metastatic pancreatic cancer. European Society of Medical Oncology (ESMO): 2010; Abstract 712OD
120. Goldstein L. J OC, Heinrich B., et al. A randomized double-blind phase II study of the combination of WX-671 plus capecitabine vs. capecitabine monotherapy in first-line HER-2 negative metastatic breast cancer (MBC). Cancer Res: 2012; 72 24 P5- 20 21
121. Garner R. L., Tillett W. S. Biochemical studies on the fibrinolytic activity of hemolytic streptococci: I. isolation and characterization of fibrinolysin. J Exp Med: 1934; 60 2 239 254
122. Garner R. L., Tillett W. S. Biochemical Studies on the Fibrinolytic Activity of Hemolytic Streptococci: Ii. Nature of the Reaction. J Exp Med: 1934; 60 2 255 267
123. Johnson A. J., Tillett W. S. The lysis in rabbits of intravascular blood clots by the streptococcal fibrinolytic system (streptokinase). J Exp Med: 1952; 95 5 449 464
124. Nydick I., Ruegsegger P., Abarquez R., Cliffton E. E., Ladue J. S. The effect of fibrinolytic agents on myocardial infarction. Prog Cardiovasc Dis: 1960; 3 13 28
125. Clarke R. L., Cliffton E. E. The treatment of cerebrovascular thromboses and embolism with fibrinolytic agents. Am J Cardiol: 1960; 6 546 551
126. Sherry S., Alkjaersig N. Biochemical experimental, and clinical studies of proteolytic enzymes with particular reference to the fibrinolytic enzyme of human plasma. Ann N Y Acad Sci: 1957; 68 1 52 66
127. Ambrus J. L., Ambrus C. M., Back N., Sokal J. E., Collins G. L. Clinical and experimental studies on fibrinolytic enzymes. Ann N Y Acad Sci: 1957; 68 97 136, discussion 136-137
128. Fletcher A. P., Sherry S., Alkjaersig N., Smyrniotis F. E., Jick S. The maintenance of a sustained thrombolytic state in man. II. Clinical observations on patients with myocardial infarction and other thromboembolic disorders. J Clin Invest: 1959; 38 7 1111 1119
129. Johnson A. J., McCARTY W. R. The lysis of artificially induced intravascular clots in man by intravenous infusions of streptokinase. J Clin Invest: 1959; 38 1627 1643
130. Kaste M. Stroke: advances in thrombolysis. Lancet Neurol: 2013; 12 1 2 4
131. del Zoppo G. J. Plasminogen activators and ischemic stroke: conditions for acute delivery. Semin Thromb Hemost: 2013; 39 4 406 425
132. Boucek R. J., Murphy W. P. 18 Segmental perfusion of the coronary arteries with fibrinolysin in man following a myocardial infarction. Am J Cardiol: 1960; 6 525 533
133. Dotter C. T., Rösch J., Seaman A. J. Selective clot lysis with low-dose streptokinase. Radiology: 1974; 111 1 31 37
134. Oklu R., Wicky S. Catheter-directed thrombolysis of deep venous thrombosis. Semin Thromb Hemost: 2013; 39 4 446 451
135. Wicky S., Pinto E. G., Oklu R. Catheter-directed thrombolysis of arterial thrombosis. Semin Thromb Hemost: 2013; 39 4 441 445
136. Van De Craen B., Declerck P. J., Gils A. The Biochemistry, Physiology and Pathological roles of PAI-1 and the requirements for PAI-1 inhibition in vivo. Thromb Res: 2012; 130 4 576 585
137. Vaughan D. E. PAI-1 antagonists: the promise and the peril. Trans Am Clin Climatol Assoc: 2011; 122 312 325
138. Vaughan D. E., De Taeye B. M., Eren M. PAI-1 antagonists: predictable indications and unconventional applications. Curr Drug Targets: 2007; 8 9 962 970 (Pubitemid 47578144)
139. Declerck P. J., Gils A. Three decades of research on plasminogen activator inhibitor-1: a multifaceted serpin. Semin Thromb Hemost: 2013; 39 4 356 364
140. Van De Craen B., Scroyen I., Vranckx C., et al. Maximal PAI-1 inhibition in vivo requires neutralizing antibodies that recognize and inhibit glycosylated PAI-1. Thromb Res: 2012; 129 4 e126 e133
141. Izuhara Y., Yamaoka N., Kodama H., et al. A novel inhibitor of plasminogen activator inhibitor-1 provides antithrombotic benefits devoid of bleeding effect in nonhuman primates. J Cereb Blood Flow Metab: 2010; 30 5 904 912
142. Yamaoka N., Kawano Y., Izuhara Y., Miyata T., Meguro K. Structure-activity relationships of new 2-acylamino-3-thiophenecarboxylic acid dimers as plasminogen activator inhibitor-1 inhibitors. Chem Pharm Bull (Tokyo): 2010; 58 5 615 619